Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Giapreza

&times

Overview

What is Giapreza?

Angiotensin II is a naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure. GIAPREZA is a sterile, aqueous solution of synthetic human angiotensin II for intravenous administration by infusion. Each 1 mL of GIAPREZA contains 2.5 mg angiotensin II equivalent to an average of 2.9 mg angiotensin II acetate, 25 mg mannitol, and Water for Injection adjusted with sodium hydroxide and/or hydrochloric acid to pH of 5.5.

The chemical name of the synthetic angiotensin II acetate is L-Aspartyl-L-arginyl-L-valyl-Ltyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine, acetate salt. The counter ion acetate is present in a non-stoichiometric ratio. It is a white to off-white powder, soluble in water.

The structure of angiotensin II acetate is shown below.

Molecular formula: C

H

N

O

∙ (C

H

O

)

; (n= number of acetate molecules; theoretical n = 3)

Average molecular weight: 1046.2 (as free base).



What does Giapreza look like?



What are the available doses of Giapreza?

Injection: 2.5 mg/mL and 5 mg/2 mL (2.5 mg/mL) in a vial.

What should I talk to my health care provider before I take Giapreza?

How should I use Giapreza?

GIAPREZA increases blood pressure in adults with septic or other distributive shock.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

GIAPREZA must be administered as an intravenous infusion. GIAPREZA must be diluted in 0.9% sodium chloride prior to use. Dilute the contents of one vial of GIAPREZA in 0.9% saline to achieve a final concentration of 5,000 ng/mL or 10,000 ng/mL.

Discard vial and any unused portion of the drug product after use.

Diluted solution may be stored at room temperature or under refrigeration. Discard prepared solution after 24 hours at room temperature or under refrigeration.


What interacts with Giapreza?

Sorry No Records found


What are the warnings of Giapreza?

Sorry No Records found


What are the precautions of Giapreza?

Sorry No Records found


What are the side effects of Giapreza?

Sorry No records found


What should I look out for while using Giapreza?

None.


What might happen if I take too much Giapreza?

Overdose of GIAPREZA would be expected to result in hypertension, necessitating close monitoring and supportive care. Effects are expected to be brief because the half-life of angiotensin II is less than one minute.


How should I store and handle Giapreza?

Mysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLCMysoline TabletsEach square-shaped, scored, yellow tablet, identified by "MYSOLINE 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)Each square-shaped, scored, white tablet, identified by "MYSOLINE 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)StorageStore at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure.Manufactured for: Manufactured by:Piramal Enterprises LimitedPlot No. 67-70, Sector II, Dist. DharPithampur, Madhya Pradesh 454775 IndiaMysoline is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.© Valeant Pharmaceuticals North America LLC


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.

Non-Clinical Toxicology
None.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).